Researcher
Medivation, Inc., San Francisco, CA
Study Review
The EMBRACA study compared the safety and effectiveness of the PARP inhibitor talazoparib to commonly used chemotherapy drugs in people with an inherited BRCA1 or BRCA2 mutation diagnosed with locally advanced or metastatic breast cancer. The researchers wanted to enroll 429 participants and used the Army of Women (AOW) as one of their recruitment sources. The Call to Action for this study was sent to AOW members on November 16, 2016. The researchers were able to close enrollment on April 25, 2017, after the AOW provided them with 6 volunteers who were interested in enrolling in the study.
